Skip to main content

Table 1 Clinical and molecular characteristics of the CRC subgroups stratified by peroxisome score and TIM3 expression

From: Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer

  n = 1149 Group I + II
(PeroxisomeHigh)
n = 574 (50%)
Group III
(PerLowTIM3High)
n = 263 (23%)
Group IV
(PerLowTIM3Low)
n = 312 (27%)
p
Age (years)
 <  65 445 239 (54%) 86 (19%) 120 (27%)  
 ≥ 65 704 335 (48%) 177 (25%) 192 (27%) 0.048
Gender
 Female 526 261 (49%) 119 (23%) 146 (28%)  
 Male 623 313 (50%) 144 (23%) 166 (27%) 0.913
Stage
 I 133 74 (56%) 18 (14%) 41 (31%)  
 II 474 253 (53%) 110 (23%) 111 (23%)  
 III 371 169 (46% 94 (25%) 108 (29%)  
 IV 147 65 (44%) 37 (25%) 45 (31%) 0.020
Location
 Left colon, rectum 549 277 (50%) 114 (21%) 158 (29%)  
 Right colon 578 146 (25%) 146 (25%) 286 (50%) 0.149
Microsatellite
 MSI 150 64 (43%) 66 (44%) 20 (13%)  
 MSS 949 480 (51%) 178 (19%) 291 (31%) < 0.001
CMS
 CMS1 160 65 (41%) 77 (48%) 18 (11%)  
 CMS2 445 274 (62%) 42 (9%) 129 (29%)  
 CMS3 136 89 (65%) 10 (7%) 37 (27%)  
 CMS4 253 74 (29%) 106 (42%) 73 (29%)  
 Indeterminate 106 54 (51%) 24 (23%) 28 (26%) < 0.001
KRAS status
 Mutated 374 192 (51%) 92 (25%) 90 (24%)  
 Wild-type 664 314 (47%) 156 (23%) 194 (29%) 0.197
BRAF status
Mutated 102 36 (35%) 48 (47%) 18 (18%)  
Wild-type 903 455 (50%) 192 (21%) 256 (28%) < 0.001
TP53 status
 Mutated 496 222 (45%) 97 (20%) 177 (36%)  
 Wild-type 351 191 (54%) 76 (22%) 84 (24%) 0.001
CIMP
 High 164 64 (39%) 70 (43%) 30 (18%)  
 Low 771 420 (54%) 159 (21%) 192 (25%) < 0.001